Evaluation of patients using the LATITUDE monitoring system for heart devices

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects and analyzes data from patients who receive cardiac implantable electrical devices (CIEDs) that communicate remotely through the LATITUDE monitoring system. It aims to create a shared environment for physicians across Europe to manage and report clinical data related to these devices. The study will facilitate collaboration among researchers and document experiences with medical devices throughout their lifecycle, enhancing understanding of their effectiveness and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject is willing and capable of providing informed consent to collect/store/process personal health information by the sponsor or such consent is provided by a legally designated representative, if required by local law or regulation.
* Subject is:

  1. prospectively scheduled for receiving a device monitored through the LATITUDE monitoring system
  2. retrospectively enrolled after having received a device monitored through the LATITUDE monitoring system

Exclusion Criteria:

* Subject foreseen not to be followed at the enrolling center for at least 1 year after having received the device.
* Subject is receiving a device that is not approved for commercial use at the time of procedure.

Where it's running

• Azienda Ospedaliero-Universitaria di Ferrara
  Ferrara, Italy Recruiting
• Policlinico Federico II
  Naples, Italy Recruiting
• Ospedale "G.B. Grassi"
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Matteo Bertini, Prof — Azienda Ospedaliera Universitaria di Ferrara
• Study coordinator: Matteo Bertini, Prof
• Email: doc.matber@gmail.com
• Phone: +390532236111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Dapagliflozin to Improve Exercise and Heart Function in Fontan Patients

  This study tests whether the diabetes drug dapagliflozin can improve exercise capacity and heart function in people who had a Fontan procedure.

  Recruiting Phase 4 The University of Hong Kong · Hong Kong and 1 other locations · NCT07482943

• Vicadrostat versus spironolactone: effects on kidney function and protein markers

  This will test whether vicadrostat or spironolactone, each given with empagliflozin, changes kidney function and blood/urine protein patterns in adults with CKD and heart disease or heart failure.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen and 1 other locations · NCT07304817

• Pacing decisions guided by risk for pacing-induced heart muscle weakness

  This study tests a risk score to predict pacing-induced cardiomyopathy in adults getting heart rhythm devices, to tailor pacing choices.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Canberra, Australian Capital Territory and 12 other locations · NCT07276139

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.